

## Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis

Aurélien Delluc,<sup>1</sup> Sébastien Miranda,<sup>2</sup> Paul den Exter,<sup>3</sup> Martha Louzada,<sup>4</sup> Adriano Alatri,<sup>5</sup> Shin Ahn,<sup>6</sup> Manuel Monreal,<sup>7</sup> Alok Khorana,<sup>8</sup> Menno V. Huisman,<sup>3</sup> Philip S. Wells<sup>1</sup> and Marc Carrier<sup>1</sup>

<sup>1</sup>Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Ontario, Canada; <sup>2</sup>Normandie University, UNIROUEN, INSERM U1096 and Rouen University Hospital, Department of Internal Medicine, Vascular and Thrombosis Unit, F 76000 Rouen, France; <sup>3</sup>Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands; <sup>4</sup>Department of Medicine, Division of Hematology, University of Western Ontario, London, Ontario, Canada; <sup>5</sup>Division of Angiology, Lausanne University Hospital, Lausanne, Switzerland; <sup>6</sup>Department of Emergency Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; <sup>7</sup>Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain and <sup>8</sup>Cleveland Clinic-Taussig Cancer Center, Cleveland, OH, USA

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.222828

Received: March 27, 2019.

Accepted: June 28, 2019.

Pre-published: July 4, 2019.

Correspondence: *AURÉLIEN DELLUC* - [adelluc@toh.ca](mailto:adelluc@toh.ca)


---

**Appendix 1: Summary of retrieved studies and their quality evaluation (10)**


Author, year	Score	Study participation	Study attrition	Prognosis factor measurement	Outcome measurement	Confounding measurement and account	Analysis
Louzada derivation (2012) (9)	Original Modified	Yes	No	Yes	Yes	No	Yes
Louzada validation (2012) (9)	Modified	Yes	No	Yes	Yes	Partly	Yes
Louzada validation (2012) (14)	Original	Yes	No	Yes	Yes	No	Yes
Den Exter (2013) (17)	Modified	Yes	No	No*	Yes	No	Yes
Ahn (2013) (19)	Original	Partly	No	Yes	Yes	No	Yes
Astruc (2016) (13)	Modified	Yes	No	No*	Yes	No	Yes
Alatri (2017) (16)	Modified	Yes	No	Yes	Yes	No	Yes
Khorana (2017) (18)	Modified	Yes	Yes	Yes	Yes	Partly	Yes
Van Es (2018) (15)	Original	Yes	No	Yes	Yes	No	Yes

\* exact cancer stage was not recorded


**Appendix 2:** Funnel plots for risk estimates in the meta-analysis (A: all scores, B: original score, C: modified score)



**A**



**B**



**C**

**Appendix 3:** Pooled incidence of recurrent VTE in each sum of points category

Sum of points	Original		Modified	
	Incidence % (95% CI)	$I^2$ (%)	Incidence % (95% CI)	$I^2$ (%)
-2	0 (0.00-1.01)	17%	0 (0.00-16.82)	-
-1	4.88 (0.85-10.86)	0%	2.23 (1.64-2.90)	0
0	7.29 (2.50-14.10)	84%	7.77 (3.74-13.05)	92%
+1	16.75 (13.03-20.82)	34%	9.52 (5.77-14.05)	88%
+2	26.85 (16.95-37.96)	44%	8.95 (3.68-15.75)	67%
+3	37.13 (12.66-64.73)	0	9.07 (0.17-24.67)	5%